Core Viewpoint - Zhaoli Pharmaceutical is acquiring a multi-element injection asset group for 356 million yuan, aiming to enhance its product portfolio and market presence in the pediatric and obstetric fields [1][4][11]. Group 1: Acquisition Details - Zhaoli Pharmaceutical announced the acquisition of the multi-element injection asset group from Tibet Future Biopharmaceutical Co., Ltd. for a total price of 356 million yuan, including tax [1][11]. - The asset group includes three types of multi-element injections, specifically designed for infants, pregnant women, and patients requiring intravenous nutrition [2][13]. Group 2: Strategic Intent - The acquisition is part of Zhaoli Pharmaceutical's strategy to create a comprehensive health product and service chain covering all age groups, from children to the elderly [2][14]. - The company aims to leverage its existing marketing strengths and the sales channels of Tibet Future to facilitate the rapid entry and penetration of new products [15]. Group 3: Financial Performance - The asset group is projected to achieve a net profit of 45.79 million yuan from January to September 2025, indicating strong profitability [3][14]. - Zhaoli Pharmaceutical reported a revenue of 2.28 billion yuan in the first three quarters of 2025, reflecting an 11.48% year-on-year growth, with a net profit of 509 million yuan, up 22.51% [4][17]. Group 4: Market Context - The multi-element injection market has seen a decline in sales since 2021, with a total market sales of only 1.44 billion yuan in 2024, down 16.32% year-on-year [8][20]. - The competitive landscape is concentrated, with Aquitaine Pharmaceuticals holding a dominant market share of 50.45%, while Tibet Future's sales have decreased by 22.17% to 447 million yuan in 2024 [20][22].

Core Viewpoint - Zhaoli Pharmaceutical (300181.SZ) announced the acquisition of a multi-trace element injection asset group from Tibet Future Biopharmaceutical Co., Ltd. for a total price of RMB 356 million, which includes both marketed and research products, enhancing the company's product structure and expanding its treatment areas [1][2]. Group 1 - The acquisition includes the marketed products "Multi-trace Element Injection (I)" and "Multi-trace Element Injection (II)", as well as the research product "Multi-trace Element Injection (III)" [1]. - The asset group is expected to optimize the company's product structure and broaden its focus on disease treatment and health management for women, children, and the elderly, aligning with the national health development strategy [1]. - The asset group generated a net profit of RMB 45.79 million from January to September 2025, indicating strong profitability [2].

Core Viewpoint - Zhaoli Pharmaceutical (300181.SZ) announced the acquisition of a multi-trace element injection asset group from Tibet Future Biopharmaceutical Co., Ltd. for a total price of RMB 356 million, which will enhance the company's product structure and expand its treatment areas, particularly focusing on women's, children's, and elderly health management [1][2]. Group 1 - The acquisition includes the research and production technical data, marketing licenses, trademarks, patents, and employee labor relations related to the already marketed products "Multi-trace Element Injection (I)" and "Multi-trace Element Injection (II)", as well as the in-development "Multi-trace Element Injection (III)" [1]. - The acquisition is aligned with the national health development strategy, aiming to establish a comprehensive health product and service chain covering all age groups from children to the elderly [1]. - The asset group has demonstrated strong profitability, with a net profit of RMB 45.79 million achieved from January to September 2025, indicating good earning potential [2].